Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. 2013

Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands;, †Department of Nephrology, UNIFESP, Sao Paolo, Brazil, ‡Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.

OBJECTIVE Circulating fibroblast growth factor 23 (FGF23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown. METHODS The association between plasma C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center prospective cohort of 593 stable kidney transplant recipients (mean age ± SD, 52 ± 12 years; 54% male; estimated GFR, 47 ± 16 ml/min per 1.73 m(2)), at a median of 6.1 (interquartile range, 2.7-11.7) years after transplantation. Multivariate Cox regression models were built, adjusting for measures of renal function and mineral metabolism; Framingham risk factors; the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-pro brain natriuretic peptide (NT-proBNP); and copeptin, the stable C-terminal portion of the precursor of vasopressin. RESULTS In multivariate linear regression analysis, MR-proANP (β=0.20, P<0.001), NT-proBNP (β=0.18, P<0.001), and copeptin (β=0.26, P<0.001) were independently associated with FGF23. During follow-up for 7.0 (interquartile range, 6.2-7.5) years, 128 patients (22%) died, of whom 66 (11%) died due to cardiovascular disease; 54 (9%) had graft failure. FGF23 was associated with an higher risk of cardiovascular mortality in a fully adjusted multivariate Cox regression model (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.11 to 3.19]; P=0.02). FGF23 was also independently associated with all-cause mortality (full model HR, 1.86 [95% CI, 1.27 to 2.73]; P=0.001). Net reclassification improved for both cardiovascular mortality (HR, 0.07 [95% CI, 0.01 to 0.14]; P<0.05) and all-cause mortality (HR, 0.11 [95% CI, 0.05 to 0.18]; P<0.001). CONCLUSIONS Plasma FGF23 is independently associated with cardiovascular and all-cause mortality after kidney transplantation. The association remained significant after adjustment for measures of mineral metabolism and cardiovascular risk factors.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D005346 Fibroblast Growth Factors A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family. DNA Synthesis Factor,Fibroblast Growth Factor,Fibroblast Growth Regulatory Factor,Growth Factor, Fibroblast,Growth Factors, Fibroblast
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide

Related Publications

Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
June 2020, Journal of clinical medicine,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
January 2014, International urology and nephrology,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
February 2011, Pediatric transplantation,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
January 2017, American journal of nephrology,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
July 2012, Clinical journal of the American Society of Nephrology : CJASN,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
April 2009, The International journal of artificial organs,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
November 2015, Pediatric nephrology (Berlin, Germany),
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
December 2021, Kidney international,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
May 2011, Journal of the American Society of Nephrology : JASN,
Leandro C Baia, and Jelmer K Humalda, and Marc G Vervloet, and Gerjan Navis, and Stephan J L Bakker, and Martin H de Borst, and
August 2012, Pediatric transplantation,
Copied contents to your clipboard!